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 INTRODUCTION 
 
  Diabetes mellitus (DM) comprises a group of common 
metabolic disorders that share the phenotype of hyperglycemia. 
The metabolic dysregulation associated with DM causes secondary 
pathophysiologic changes in multiple organ systems that impose a 
tremendous burden on the individual with Diabetes and on the 
health care system. DM is one of the leading cause of end stage 
renal disease (ESRD), non traumatic lower extremity amputations 
and adult blindness. Diabetes is one of the leading cause of 
cardiovascular and cerebrovascular diseases. With increasing 
incidence Worldwide, DM will be a leading cause of morbidity and 
mortality for foreseeable future. 
Hypertension is a very common comorbid condition in 
Diabetes. In type 2 Diabetes, Hypertension usually clusters with 
other components of cardiometabolic syndrome such as 
microalbuminuria, central obesity, insulin resistance, dyslipidemia, 
hypercoagulation, increased inflammation, LVH and 
hyperuricemia.  
Hypertension, as an independent risk factor for 
atherogenesis, synergizes with effects of diabetes and significantly 
increases the development and progression of coronary artery 
disease, cerebrovascular disease and peripheral vascular disease. 
Hypertension also predisposes to the development of certain 
microvascular complications of diabetes such as nephropathy and 
retinopathy.  
Diabetes and hypertension are the 2 important causes of 
morbidity and mortality and imposing a tremendous burden on 
health care system. 
AIM OF THE STUDY 
 
 To compare the prevalence of Micro and Macrovascular 
complications of diabetes mellitus among type 2 DM patients, 
with and without hypertension.  
 To study the influence of hypertension on the vascular 
complications of type 2 DM. 
 
REVIEW OF LITERATURE 
 
CHRONIC COMPLICATIONS OF DIABETES MELLITUS  
The chronic complications of DM affect many organ systems 
and are responsible for the majority of morbidity and mortality 
associated with the disease.  
Chronic complications can be divided into vascular and non-
vascular complications 
Vascular Non Vascular 
Microvascular   
Eye Disease  
 -    Retinopathy 
      (Non proliferative /        
              proliferative) 
 -    Macular Edema 
Neuropathy  
- Sensory and Motor  
- Autonomic  
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Macrovascular  
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Cerebrovascular Disease  
-  Gastrointestinal 
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-  Infectious  
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MICROVASCULAR COMPLICATIONS OF DIABETES 
Diabetic Neuropathy 
Diabetic neuropathy occurs commonly in individuals with 
long standing Type 1 or Type 2 DM. The development of 
neuropathy correlates with the duration of diabetes and glycemic 
control. Both myelinated and unmyelinated nerve fibers are lost. 
Pathogenesis of Diabetic Neuropathy   
Hyperglycemia is the central factor. Following mechanisms 
mediates the effects of chronic hyperglycemia in the pathogenesis of 
diabetic neuropathy :- 
¾ Genetic predisposition  
¾ Nerve hypoxia / ischemia1 
¾ Oxidative stress2 
¾ Overactivity of polyol pathway3 
¾ Increased advanced glycation end products4 
¾ Deficiency of γ- linolenic acid 
¾ Protein Kinase C, especially increase in β - isoform. 
¾ Growth factors deficiency 
¾ Dysimmune mechanism 
Classification of Diabetic Neuropathy 
Symmetric Neuropathies 
Focal and multifocal 
neuropathies 
Distal symmetric sensori motor 
polyneuropathy 
Cranial neuropathy 
Autonomic neuropathy Thoraco abdominal 
neuropathy 
Acute painful neuropathy Focal limb neuropathy 
Hyperglycemic neuropathy Diabetic amyotrophy 
Treatment induced neuropathy  
Symmetric proximal lower 
extremity neuropathy  
 
 
Autonomic Neuropathy 
 Individuals with long standing type 1 or type 2 DM may 
develop signs of autonomic dysfunction involving the cholinergic, 
noradrenergic and peptidergic systems. DM related autonomic 
neuropathy can involve multiple systems, including the 
cardiovascular, gastrointestinal, genitourinary, sudomotor, and 
metabolic systems. Autonomic neuropathy may reduce counter 
regulatory hormone release, leading to an inability to sense 
hypoglycemia appropriately, thereby subjecting the patient to the 
risk of severe hypoglycemia and complicating efforts to improve 
glycemic control.  
Treatment of Diabetic Neuropathy 
Treatment of diabetic neuropathy is less satisfactory. 
Symptoms of diabetic neuropathy improves less even after proper 
glycemic control. Efforts to improve glycemic control may be 
confounded by autonomic neuropathy and hypoglycemia 
unawareness. Avoidance of neurotoxins (alcohol), supplementation 
for possible deficiencies (B12, B6, Folate) and symptomatic 
treatment are the mainstays of therapy. Loss of sensation in the 
foot places the patient at risk for ulceration and its sequelae. 
Prevention of such problems is important. Chronic painful diabetic 
neuropathy is difficult to treat, but may respond to tricyclic 
antidepressants, gabapentin, NSAIDs and other agents such as 
Mexilitine, phenytoin, Carbamazepine and Capsaicin cream. 
Therapy of orthostatic hypotension secondary to autonomic 
neuropathy is challenging. A variety of agents such as 
fludrocortisone, midodrine, clonidine, octreotide and yohimbine 
have been tried. Non pharmacologic maneuvers (adequate salt 
intake, avoidance of dehydration and diuretics and lower extremity 
support hose) offer some benefit.  
Diabetic Retinopathy 
Diabetic retinopathy is one of the leading cause of adult 
blindness. Duration of DM and degree of glycemic control are the 
best predictors of the development of retinopathy. Hypertension is 
one of the most important risk factor. Because diabetic retinopathy 
is often asymptomatic in its most treatable stages, early detection 
of retinopathy through regularly scheduled ocular examination is 
critical. Blindness usually results from non-resolving vitreous 
haemorrhage, traction retinal detachment or diabetic macular 
edema. In type 2 DM, most often patients have retinopathy at 
diagnosis, reflecting its long asymptomatic period of hyperglycemia 
in type 2 DM. 
UKPDS5,6 enrolled 3,687 patients with newly diagnosed type 
2 diabetes. Intensive therapy to control blood glucose, using either 
sulfonylureas or Insulin resulted in a 17% risk reduction for 
progression of diabetic retinopathy, a 29% risk reduction in the 
need for laser photocoagulation surgery, a 23% risk reduction for 
the development of vitreous haemorrhage and a 16% risk reduction 
in legal blindness. 
Conditions that may affect course of diabetic retinopathy 
¾ Hypertension7 
¾ Elevated lipids 8 
¾ Proteinuria; elevated creatinine level9 
¾ Cardiovascular disease  
International classification of Diabetic retinopathy10 
5 Clinical levels of DR : 
¾ No apparent retinopathy (No abnormality). 
¾ Mild non proliferative diabetic retinopathy (NPDR) 
(Microaneurysms only). 
¾ Moderate NPDR (more than microaneurysms only but less 
than severe NPDR). 
¾ Severe NPDR (any of the following : > 20 Intraretinal 
haemorrhages in each 4 quadrants, definite venous beading 
in 2+ Quadrants, prominent intraretinal microvascular 
abnormalities in 1+ quadrant and no PDR). 
¾ Proliferative Diabetic retinopathy (PDR) (1 or more of retinal 
neovascularization, vitreous haemorrhage or preretinal 
haemorrhage). 
International clinical Diabetic macular edema scale10 
2 broad levels 
1. Macular edema apparently absent (No apparent retinal 
thickening or hard exudates in posterior pole). 
2. Macular edema  apparently present. 
Mild – Some apparent retinal thickening or hard exudates in 
posterior pole but distant from centre of macula. 
Moderate – Retinal  thickening or hard exudates 
approaching centre of macula but not involving centre. 
Severe -  retinal thickening or hard exudates involving 
centre of macula.  
Treatment of Diabetic Retinopathy 
The most effective therapy for diabetic retinopathy is 
prevention. Intensive glycemic and BP control will delay the 
development or slow the progression of retinopathy in individuals 
with either type 1 or type 2 DM. Individuals with known 
retinopathy are candidates for prophylactic photocoagulation, while 
initiating intensive therapy. Once advanced retinopathy is present, 
improved glycemic control imparts less benefit, though adequate 
ophthalmologic care can prevent most of blindness. Regular, 
comprehensive eye examinations are essential for all individuals 
with DM. Most diabetic eye disease can be successfully treated if 
detected early. Laser photocoagulation is very successful in 
preserving vision. Proliferative retinopathy is treated with 
panretinal laser photocoagulation, whereas macular edema is 
treated with focal laser photocoagulation. 
Diabetic Nephropathy 
 Diabetic nephropathy occurs in 30-50% of patients with type 
1 or type 2 diabetes11 and is the leading cause of Endstage renal 
disease worldwide. The increasing incidence of diabetic 
nephropathy in patients with type 2 DM is in part, the result of 
greater success in decreasing mortality due to type 2 diabetes. 
Improved management of cardiovascular complications of type 2 
diabetes through better control of lipids and improved and more 
stringent BP control has significantly increased life expectancy and 
the time for other complications to develop.  
 One of the earliest sign of renal involvement in diabetes is an 
increase in albumin excretion12 (30-300 mg/day) Albumin excretion 
rate (AER) varies from 20-200 µg/minute. This stage is referred to 
as the “Microalbuminuria” stage which is albustix negative. Its 
therapeutic importance lies on the fact that it is reversible by tight 
glycemic control. With further progression of Diabetic nephropathy, 
persistent albuminuria is referred to as “Macroalbuminuria” 
heralding the onset of clinical Diabetic nephropathy. At this stage, 
urinary albumin excretion is > 300 mg/day and AER > 200 µg/min. 
Macroalbuminuria is albustix positive.  
 Hypertension plays a critical role in the progression of 
Diabetic nephropathy. Indeed, the development of proteinuria is 
paralleled in most cases by a gradual rise in systemic BP. There is 
a significant correlation between BP levels and rate of decline in 
glomerular filtration rate13. Interventional studies in humans and 
animals have demonstrated significant renoprotective and 
antiproteinuric effects of antihypertensive therapy14.  
In diabetic nephropathy, hypertension is not merely the 
result of relentless kidney damage, there is clinical evidence that 
elevated BP is also important in genesis of glomerular lesion. 
Prospective studies in type 1 and type 2 diabetic subjects have 
demonstrated that mean arterial BP levels are significantly higher 
in those who progress to microalbuminuria, that in those who do 
not progress15.  
Under normal conditions, intraglomerular capillary pressure 
is tightly regulated by pressure adjustments in afferent and 
efferent arteriolar resistance. Hyperglycemia induces 
vasodilatation and in diabetes, there is marked reduction in 
afferent and a lesser reduction in efferent arteriolar resistance. 
This leads to an increase in the levels of glomerular capillary 
pressure and moreover allows ready transmission of any increase 
in systemic BP to the glomerular capillary network16.  
Diagnosis of Diabetic Nephropathy 
100% of patients with Diabetic nephropathy have 
albuminuria. Its absence should seek an alternate diagnosis.  
The urinary sediment is unremarkable – There are usually 
no casts, no RBCs and no WBCs. 
Majority of patients have retinopathy before the onset of 
diabetic kidney disease.  
Duration of the disease is also important. It is unusual to 
diagnose diabetic nephropathy before 5 years of Diabetes. Deviation 
from any of the above association should prompt a search for 
alternative diagnosis in a patient with diabetic kidney disease.  
Treatment of Diabetic Nephropathy 
 The optimal therapy for diabetic nephropathy is prevention. 
Microalbuminuria should be detected at an early stage, when 
effective therapies can be instituted. Interventions effective in 
slowing the progression from microalbuminuria to overt 
nephropathy include 1) near normalization of glycemia 2) strict BP 
control 3) administration of ACE inhibitors or ARBs and 4) 
treatment of dyslipidemia.  
 During the phase of declining renal function, insulin 
requirements may fall as the kidney is a site of insulin degradation. 
Oral hypoglycemic drugs are contraindicated in advanced renal 
insufficiency. 
 Numerous studies in both type 1 and type 2 DM demonstrate 
the effectiveness of strict BP control in reducing albumin excretion 
and slowing the decline in renal function. BP should be maintained 
at < 130/80mmHg in diabetic individuals without proteinuria. A 
target of < 125/75mmHg should be considered for individuals with 
proteinuria > 1g/day. 
 ACE inhibitors and ARBs reduce the progression of overt 
nephropathy and should be prescribed in individuals with type 1 or 
type 2 DM and microalbuminuria. 
 Nephrology consultation should be considered after the 
diagnosis of early incipient nephropathy. The risk of complications 
during hemodialysis in Diabetic patients is more when compared to 
non diabetic patients. Atherosclerosis is the leading cause of death 
in diabetic individual on dialysis. Renal transplantation from a 
living related donor is the preferred therapy. Combined pancreas-
kidney transplant offers the promise of normoglycemia.  
MACROVASCULAR COMPLICATIONS 
Coronary artery disease  
 Diabetes mellitus is a major independent risk factor for 
cardiovascular disease17 (CVD). Increased prevalence of CVD in 
diabetes has been attributed to the acceleration of coronary 
atherosclerosis, which occurs at earlier age and advances more 
rapidly to clinical cardiovascular events in individuals with 
diabetes than those without diabetes18. Coronary heart disease 
(CHD) in diabetes is diffuse with increase in number of affected 
vessels. Furthermore, autonomic neuropathy in patients with 
diabetes reduce the symptoms of CHD19, delay its detection and 
worsen the prognosis. Diabetic individuals are faced with increased 
restenosis and mortality rates following revascularization 
procedures  especially for percutaneous transluminal coronary 
angioplasty (PTCA).  
 Hypertension is a major CVD risk factor that often coexists 
with Insulin resistance and diabetes20. The UKPDS21 has shown 
that tight BP control substantially reduces the risk of 
macrovascular events in patients with type 2 DM. This study 
showed that for each 10mmHg reduction from ≤ 160 to < 120 mm 
Hg of systolic BP, there was 11% reduction in myocardial 
Infarction. Combination of CVD risk factors frequently coexist in 
individuals with Insulin resistance and diabetes. Because these 
CVD risk factors can develop years before the onset of type 2 DM, it 
is likely that pathogenesis of CVD in patients with type 2 DM 
begins well before the diagnosis of diabetes.  
RISK FACTORS FOR CVD IN DIABETES  
Metabolic factors 
Coagulation, 
inflammatory 
factors 
Vascular related 
factors 
Hyperglycemia  ↑ PAI – 1 Hypertension  
Insulin resistance ↑ Platelet activation  Impaired 
endothelial 
dependent 
vasodilatation 
Hyperinsulinemia  ↑ Fibrinogen  ↑ Arterial  
calcification  
↓ HDL cholesterol  ↑ P- selectin, 
VCAM-1 and ICAM 
↓ Arterial 
compliance  
Small dense LDL ↑ Tissue factor and 
factor VII 
 
Hyperhomocysteinemia ↓ Nitric oxide bio 
availability  
 
 ↑ CRP  
Treatment  
 In general, the treatment of coronary artery disease is no 
different in the diabetic subjects. Revascularization procedures for 
coronary artery disease such as percutaneous coronary 
interventions (PCI) and coronary artery bypass grafting (CABG), 
are less efficacious in the diabetic individual. Initial success rates of 
PCI in diabetic patients are similar to those in the non – diabetic 
patients, but diabetic patients have higher rates of restenosis and 
lower long-term patency and survival rates. Recent trials indicate 
that diabetic individuals with multivessel coronary artery disease 
or recent Q-wave MI have better long term survival with CABG 
than PCI. 
 The ADA has emphasized the importance of glycemic control 
and  aggressive cardiovascular risk modification in all individuals 
with DM. ACE inhibitors and Beta blockers are particularly 
beneficial and should be considered in individuals with type 2 DM 
and other risk factors. Antiplatelet therapy reduces cardiovascular 
events in individuals with DM, who have coronary artery disease. 
Current recommendations by the ADA include the use of aspirin for 
secondary prevention of coronary events. Other risk factors such as 
hypertension, dyslipidemia should be treated properly.  

Cerebrovascular Disease  
 Diabetes is one of the most important risk factor for stroke. 
Cerebrovascular disease in diabetes usually manifests in the form 
of transient ischemic attacks and stroke. The cause of stroke in 
diabetes is mainly due to accelerated atherosclerosis. Stroke 
contributes significantly to the morbidity and mortality associated 
with diabetes. Other risk factors which contribute to the 
development and progression of cerebrovascular disease in type  
2 DM include hypertension, smoking and dyslipidemia.  
 Hypertension significantly increases the risk of developing 
stroke in type 2 DM22. The beneficial effects of strict BP control in 
reducing the incidence of stroke has been demonstrated by 
UKPDS21. In this study, there was a 44% risk reduction in stroke, 
in patients assigned to tight BP control (144/82mmHg) compared 
with patients assigned to less tight BP control (154/87 mmHg). 
HOT23 (hypertension optimal treatment) trial demonstrated 
improved cerebrovascular outcomes in patients assigned to a target 
diastolic BP of less than 80 mmHg. 
Treatment  
 The treatment of cerebrovascular disease in diabetes is 
similar to non diabetic individuals. Strict BP control and glycemic 
control forms the mainstay in the prevention and delaying the 
progression of cerebrovascular disease. Aspirin, clopidogrel, 
dipyridamole are the commonly used antiplatelet drugs in the 
prevention of TIA and stroke. Addressing other risk factors such as 
smoking, dyslipidemia is also emphasized.  
Peripheral Vascular Disease  
 Lower extremity arterial disease is more common among 
patients with diabetes, than among those without diabetes. The 
presence of diabetes is associated with a two to three fold excess 
risk of intermittent claudication, compared with its absence24. 
Despite significant advances in the prevention and treatment of 
peripheral vascular disease, diabetes continues to be the strongest 
cardiovascular risk factor for the development of critical leg 
ischemia and limb loss.  
 The cause of lower extremity ischemia in diabetes is similar 
to non- diabetic patient and is due to accelerated atherosclerosis. 
Patients with diabetes are more likely to have atherosclerotic 
disease affecting infrapopliteal arteries, with sparing of foot 
arteries25 which allows for successful arterial reconstruction to 
these distal vessels.  Conversely, the superficial femoral or popliteal 
artery is less likely to be affected by the occlusive process, allowing 
these vessels to serve as a possible inflow source for bypass 
grafting.  
 Because the foot vessels are often patent in diabetes and 
because of success of bypass grafting to these vessels, an 
appropriate evaluation for ischemia is essential in patients with 
diabetes. The complex milieu of motor and sensory neuropathy, 
thickening of capillary basement membrane, loss of neurogenic 
inflammatory response and endothelial abnormalities, all result in 
a biologically compromised foot. Unless ischemia is recognized and 
corrected, limb salvage efforts with diabetic foot will fail, even if 
infection and neuropathy have been appropriately treated.  
Treatment  
 The optimal therapy for foot ulcers and amputation is 
prevention through identification of high risk patients, education of 
the patient and institution of measures to prevent ulceration. 
Attention to other risk factors for vascular disease such as smoking, 
dyslipidemia, hypertension and improved glycemic control is 
important. Patient education should emphasize : 1. Careful 
selection of footwear 2. Daily inspection of the feet to detect early 
signs of poor – fitting footwear or minor trauma, 3. Daily foot 
hygiene to keep the skin clean and moist, 4. Avoidance  of self – 
treatment of foot abnormalities and walking bare foot 5. Prompt 
consultation with a health care provider if an abnormality arises. 
The ADA identified six interventions with demonstrated efficacy in 
diabetic foot wounds. 1. Off loading 2. Debridement 3. Would 
dressings         4. Appropriate use of antibiotics  5. 
Revascularization and 6. Limited amputation. 
DIABETES AND HYPERTENSION 
 Hypertension is a very common comorbid condition in 
diabetes. Conversely patients with hypertension are more prone to 
develop diabetes  than normotensive patients26. Hypertension is 
upto twice as common in diabetic people as in general population27, 
affecting 10-30% of type I diabetic patients and 30-50% of those 
with type 2 DM28. Hypertension is also present in 20-40% of people 
with impaired glucose tolerance29.  
MECHANISMS OF HYPERTENSION IN INSULIN RESISTANCE 
 Hypertension is associated with insulin resistance, type 2 
diabetes and other features of the metabolic syndrome. Insulin 
resistance is closely associated with high blood pressure in both 
humans and animals. There is some evidence that insulin is an 
endothelium dependent vasodilator, releasing nitric oxide (NO) 
from the endothelium, which relaxes vascular smooth muscle30,31. 
Blunting of this effect, due to insensitivity of Insulin’s action on the 
endothelium as well as on metabolically important tissues, could  
contribute to the increased peripheral resistance that is the 
hallmark of hypertension in obesity  and type 2 DM. Impaired 
endothelium mediated vasodilatation is associated with insulin 
resistant states and may play a key role in the initiation and 
progression of atherosclerosis32.  
 Insulin also has several actions that tend to raise BP and 
these are accentuated in insulin- resistant states, because 
sensitivity is preserved to the effects of the raised insulin levels. 
Insulin acts on the distal renal tubule to retain Na+ ions and 
water32,33 – an effect that still operates in insulin-resistant 
subjects34 and so could contribute to the rise in total body sodium 
content that occurs in obesity and type 2 DM35. Insulin also 
stimulates cell membrane Na+ - K+ ATPase which would raise 
intracellular Na+ concentrations in vascular smooth muscle and, by 
increasing systolic calcium levels, would enhance contractility and 
increase peripheral resistance. Through its effects on the CNS, 
insulin may stimulate the sympathetic outflow; this could also 
increase blood pressure36. Finally, insulin may stimulate the 
proliferation of vascular smooth muscle cells, which could lead to 
medial hypertrophy and increased peripheral resistance37.  
POSSIBLE  MECHANISMS OF HYPERTENSION IN 
CONDITIONS OF INSULIN RESISTANCE 
Lifestyle factors 
(diet, inactivity, 
stress, smoking) 
Genetic   
factors 
Malnutrition    
in early life 
Drugs and 
hormones 
  
  
 
 
Insulin resistance  
Metabolic tissues Endothelium 
↑ Insulin levels 
Na+ retention  ↑ Na+ - K+ ATPase 
↑ Intracellular [Na+] 
↑ Intracellular [Ca2+] 
Hypertrophy 
of vascular 
smooth 
muscle 
↓ Insulin induced 
NO Generation 
↑ Contractility of 
vascular smooth 
muscle  
↑ Peripheral 
vascular 
i t   
Abnormal 
vascular 
development 
Malnutrition 
in early life 
Hypertension  
? ? 
RELATIONSHIP BETWEEN HYPERTENSION AND 
DIABETES 
 The major cause of mortality in patients with diabetes is 
CVD38. Risk factors for CVD that cluster in diabetes include 
hypertension, central obesity, dyslipidemia, microalbuminuria, 
coagulation abnormalities, loss of nocturnal dipping of BP and 
pulse, and LVH26.  
 Hypertension is approximately twice as frequent in patients 
with diabetes as in those without diabetes27 and accounts for upto 
85% of the CVD risk. In a large prospective study of 12,550 adults, 
type 2 DM was almost 2.5 times as likely to develop in patients 
with hypertension as in their normotensive counterparts after 
adjustment for age, sex, race, education, adiposity, family history 
with respect to diabetes, physical activity level and other related 
behaviour39.  
 The association between hypertension and insulin resistance 
is well established. In untreated patients with essential 
hypertension, fasting and postprandial insulin levels were higher 
than in normotensive controls, regardless of the body mass index, 
with a direct correlation between plasma insulin concentrations 
and blood pressure. On basis of these results, it was concluded that 
essential hypertension is an insulin resistance state40.  
 Another study of 24 adults documented that patients with 
hypertension treated or untreated are insulin resistant, 
hyperglycemic and hyperinsulinemic compared with a well matched 
control group41. Insulin resistance and hyperinsulinemia are also 
present in rats with genetic hypertension, such as Dahl 
hypertensive and spontaneously hypertensive rat strains42,43. On 
the other hand, association of insulin resistance and essential 
hypertension does not occur in secondary hypertension44. These 
data suggest a common genetic predisposition for essential 
hypertension and insulin resistance, a concept that is supported by 
finding of altered glucose metabolism in normotensive off spring of 
hypertensive patients45.  
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METABOLIC DISORDERS ASSOCIATED WITH 
HYPERTENSION AND DIABETES 
¾ Central obesity 
¾ Microalbuminuria 
¾ Low HDL – cholesterol levels  
¾ High triglyceride levels  
¾ Small, dense LDL cholesterol particles  
¾ Hyperinsulinemia / Insulin resistance 
¾ Endothelial dysfunction 
¾ Increased apolipoprotein B levels  
¾ Increased fibrinogen levels 
¾ Increased PAI-1 levels 
¾ Increased C-reactive protein and other inflammatory 
markers 
¾ Absent nocturnal dipping of BP and pulse.  
¾ Left ventricular hypertrophy 
¾ Increased uric acid levels  
¾ Premature coronary artery disease.  
HEMODYNAMIC AND METABOLIC CHARACTERISTICS 
OF HYPERTENSION IN DIABETES 
Salt sensitivity and volume expansion  
 Alterations in sodium balance and extracellular fluid volume 
have heterogeneous effects on blood pressure in both normotensive 
and hypertensive subjects46. Increased salt intake does not raise BP 
in all hypertensive subjects, and sensitivity to dietary salt intake is 
greatest in the elderly; those with diabetes, renal insufficiency, and 
low renin status47,48.  
 Studies demonstrated that salt sensitivity in normotensive 
subjects is associated with a greater age-related increase in BP49. 
This is particularly important to consider in the management of 
hypertension in patients with diabetes, especially elderly persons, 
since the prevalence of both diabetes and salt sensitivity increases 
with age. Thus, a decreased salt intake along with other aspects of 
diet such as reductions in fat and free carbohydrates and increase 
in potassium are important for these patients26.  
Loss of nocturnal decline in blood pressure 
 Normotensive individuals and most patients with 
hypertension have a reproducible circadian pattern to blood 
pressure and heart rate during 24 hour ambulatory monitoring50. 
Typically, the BP is highest while the patient is awake and lowest 
during sleep, a pattern called “dipping”, in which blood pressure 
decreases by 10% to 15%. Patients with loss of nocturnal decline in 
BP, “non-dippers”, have a less than 10% decline in BP during the 
night compared with their day time BP51.   
 Patients with diabetes and many of those with the 
cardiometabolic syndrome have a loss of nocturnal dipping, as 
demonstrated by 24hour ambulatory monitoring of blood pressure. 
This is particularly important, since the loss of nocturnal dipping 
conveys excessive risk for stroke and myocardial infarction. Infact, 
ambulatory BP has been reported to be superior to office BP in 
predicting target organ involvement such as LVH52. About 30% of 
episodes of MI and 50% of strokes occur between 6.00 am and noon. 
This is particularly important in deciding strategies for the optimal 
dosing of antihypertensive medications, for which drugs that 
provide consistent and sustained 24- hour blood pressure control 
will be advantageous53.  
Microalbuminuria 
 Hypertension in type 1 diabetes is a consequence, rather than 
a cause, of renal disease and that nephropathy precedes the rise in 
BP54. Hypertension and nephropathy appear to exacerbate each 
other. In type 2 diabetes, microalbuminuria is associated with 
insulin resistance, salt sensitivity, loss of nocturnal dipping of BP 
and LVH. Elevated systolic BP is a significant determining factor 
in the progression of microalbuminuria55,56. Indeed, there is 
increasing evidence that microalbuminuria is an integral 
component of the metabolic syndrome associated with 
hypertension57. This concept is important to consider in selecting 
pharmacologic therapy for hypertension in patients with diabetes, 
for which medications that decrease both proteinuria and blood 
pressure, such as ACE inhibitors and AR blockers are used for 
reducing progression of nephropathy.  
Isolated systolic hypertension 
 With the progression of atherosclerosis in patients with 
diabetes, the larger arteries lose elasticity and become rigid. The 
systolic pressure increases disproportionately because the arterial 
system is incapable of expansion for any given volume of blood 
ejected from left ventricle, leading to isolated systolic hypertension, 
which is more common and occurs at a relatively younger age in 
patients with diabetes58.  
Orthostatic Hypotension 
 Pooling of blood in dependent veins when an individual rises 
from a recumbent position normally leads to a decrease in stroke 
volume and systolic blood pressure with concomitant increase in 
systemic vascular resistance, diastolic BP and heart rate.  
 In patients with diabetes and autonomic dysfunction, 
excessive venous pooling can cause immediate or delayed 
orthostatic hypotension, that might cause a reduction in cerebral 
blood flow, leading to lightheadedness, fatigue, unsteady gait and 
syncope59. This is important to recognize in patients with diabetes 
and concomitant hypertension because it has several diagnostic and 
therapeutic implications; for example, discontinuation of diuretic 
therapy and volume repletion might be necessary for the treatment 
of chronic orthostasis. Furthermore, increased propensity for 
orthostatic hypotension in patients with diabetes renders beta 
blockers less desirable and second line agents for these patients.  
TREATMENT OF HYPERTENSION IN PATIENTS WITH 
DIABETES 
 UKPDS21 and Hypertension optimal treatment (HOT) trial23 
demonstrated improved outcomes, in patients assigned to lower 
blood pressure targets. In HOT trial, improved outcomes were 
achieved in the group assigned to a target diastolic BP of less than 
80mmHg. A target BP of < 130/80mmHg is currently recommended 
by the seventh joint National Committee on prevention, detection, 
evaluation and treatment of high blood pressure (JNC-VII) and 
American Diabetes Association (ADA).  
Dietary and Life style Modification 
 Both JNC-VII60 and ADA61 recommend lifestyle and dietary 
modifications as an integral part of the management of 
hypertension in patients with diabetes. Importance of other CVD 
risk factors such as smoking, physical inactivity, and elevated LDL 
–cholesterol is also emphasized62.  
 Following are the dietary and lifestyle modification 
approaches in the management of Hypertension. 
1. Weight loss [maintain normal body weight (BMI 18.5 – 
24.9)]. 
2. Exercise (aerobic physical activity) 30-45 min at least 3 
times per week. 
3. Reduced sodium intake to 100 mmol (2-4g) per day. 
4. Cessation of smoking. 
5. Adequate intake of dietary potassium, calcium and 
magnesium. 
6. Reduced alcohol intake < 1Oz of ethanol per day. 
7. Diet rich in fruits and vegetables but low in fat.  
Pharmacotherapy for Hypertension in patients with 
Diabetes 
ACE Inhibitors 
 These drugs may be used in Diabetic hypertension, even in 
cases where renin angiotensin system is not activated; instead, the 
drugs may interfere with local angiotensin action in specific target 
tissues. Their ability to attenuate albuminuria and the progression 
of renal disease led to their use as renoprotective agents in diabetic 
nephropathy14,63.  
 Angiotensin converting enzyme inhibitors provide 
Cardiovascular and microvascular benefits and may also improve 
insulin resistance and prevent the development of diabetes64. In the 
studies of left ventricular dysfunction (SOLVD) trial, ACE 
inhibitors reduced left ventricular mass and left ventricular 
dilatation and significantly reduced mortality and hospitalization 
for heart failure65.  
Angiotensin II Receptor Blockers 
 JNC-VII recommended the use of AR Blockers as one of the 
several alternative first line therapy for patients with hypertension 
who do not tolerate or respond to first line medications60. AR 
Blockers were also recommended as an initial therapy for those 
who could not tolerate ACE inhibitors and in whom ACE inhibitors 
are recommended66, such as patients with diabetes and proteinuria, 
heart failure, systolic dysfunction, post MI and mild renal 
insufficiency.  
 Three major studies, reduction of End points in NIDDM with 
Angiotensin II Antagonist Losartan (RENAAL) study67, Irbesartan 
Microalbuminuria Type 2 Diabetes in Hypertensive patients (IRMA 
II) study68 and the Irbesartan in Diabetic nephropathy trial69 
(IDNT),  showed that AR blockers are effective in reducing the 
progression of renal disease in patients with type 2 diabetes and 
hypertension. 
Beta Blockers 
 Beta blockers are very useful antihypertensive agents in the 
treatment of hypertension in patients with diabetes.  In UKPDS21 
atenolol reduced microvascular complications of diabetes by 37%, 
strokes by 44% and death related to diabetes by 32%. In that study 
efficacy of beta blocker atenolol was equal to ACE inhibitor 
Captopril in reducing micro and macrovascular complications of 
diabetes, most probably secondary to their ability to modulate 
RAAS. Despite the potentially adverse effects of betablockers, they 
have significant long term favourable effects on CVD in 
hypertensive patients with diabetes.  
Calcium channel Blockers 
 For patients to achieve a target BP of 130/80mmHg, most 
studies suggest that at least 65% of them require 2 or more 
different antihypertensive agents70. With the use of ACE inhibitor 
as a first line treatment, together with a diuretic, addition of a 
long-acting dihydropyridine such as amlodipine, nifedipine or 
felodipine will reduce both proteinuria and the rate of CVD events.  
Diuretics 
 The diabetic cohort in ALLHAT71 (Antihypertensive and 
Lipid-Lowering treatment to prevent Heart attack trial) provided 
valuable information about the treatment of hypertension in older 
diabetic patients at risk for CVD. Thiazide diuretics were effective 
as part of combined therapy that reduced stroke. Therefore, they 
are recommended as preferred antihypertensive therapy.  
TREATMENT OF HYPERTENSION IN PATIENTS WITH 
DIABETES  
Treatment Goal : < 130/80 mmHg 
 
 Nonpharmacologic therapy  
Weight reduction 
Aerobic exercise 
Salt restriction 
Smoking cessation 
Restriction of alcohol intake 
Increase fiber, potassium, and calcium 
 
   
 Goal not achieved   
     
 Initiate pharmacologic therapy  
With a thiazide diuretic Continue 
nonpharmacologic therapy  
 
      
  Goal not achieved   
     
 Add a second drug in alphabetical order,  
ABC 
ACE inhibitor / AR blocker, Beta-
blocker, 
Calcium – channel blocker  
 
  
 
 
Increase drug 
dose  
 Add another agent  
 
  
 
 
 
 
Materi
als 
and 
Method
s 
MATERIALS AND METHODS  
 The study was conducted at the outpatient department,  
Dr. Ambedkar Institute of Diabetology, Kilpauk Medical College 
Hospital, during the period from February 2005 to June 2005. 
 Patients attending diabetology OPD were taken up for the 
study. 
 Two groups of patients were selected after proper inclusion 
and exclusion criteria.  
 One group in which 50 patients with type 2 DM of various 
duration of the disease,  and of either sex, without hypertension 
were selected. 
 Another group of 50 patients with both type 2 DM and 
hypertension, of various duration and of either sex were selected.  
 All the patients who were selected in both the groups were on 
treatment with oral hypoglycemic drugs or insulin for diabetes and 
antihypertensive drugs in diabetes with hypertension group, for 
various duration.  
 In diabetes with hypertension group, hypertensives were 
selected on the basis of history of treatment for hypertension. In 
patients who did not have the history of hypertension, hypertension 
was diagnosed based on JNC-VII criteria. (Seventh Joint National 
Committee on prevention, detection, evaluation and treatment of 
high blood pressure).  
 Patients, who had systolic BP 140mmHg or more and 
diastolic BP 90mmHg more were included in diabetic hypertensive 
group. Patients who had systolic BP <140mmHg and diastolic  
BP< 90mmHg were included in diabetes without hypertension 
group. 
 Smokers were excluded from both the groups.  
INCLUSION 
CRITERIA EXCLUSION CRITERIA 
Patients with type 
2 DM 
• Patients with type 1 DM  
• Smokers  
• Patients with acute illness  
• Patients with secondary hypertension 
• Patients who are over weight and 
obese (BMI 25 or more).  
 Patient’s name, age, sex, duration of DM, duration of 
hypertension were taken. Treatment history of DM and 
hypertension were taken. Family history of hypertension and 
diabetes mellitus were taken. History of complications of DM and 
treatment for them were taken. 
 All peripheral pulses were examined. BP was recorded after 
seating the patients for 5 minutes, with sphygmomanometer. Two 
recordings were taken at 2 consecutive visits. Clinically patients 
were examined for vascular bruit.  
METHODOLOGY USED TO DIAGNOSE VASCULAR 
COMPLICATIONS 
Neuropathy  
 10 gm monofilament was used to check the presence or 
absence of sensation in foot. Vibration perception threshold (VPT) 
was checked in the foot using a biothesiometer, (6 sites in the foot 
were examined great toe, 1, 3, 5 metatarsal heads, Instep, heal). 
 Peripheral neuropathy, if present was graded as mild, 
moderate and severe (VPT 11-15 V mild, 16-25 V moderate,  
> 25 V severe). 
Nephropathy  
 History of diabetic nephropathy was taken. Early morning 
urine sample was analysed for albumin using dip stick method. 2 
samples were analysed. Urine for microscopic examination was 
done to exclude active urinary sediment. Patients having urine 
albumin positive for 2 samples using dipstick method, were 
considered to have diabetic nephropathy.  
Retinopathy  
 Ocular fundus was examined by ophthalmologist after proper 
dilatation of pupil using mydriatic.  Direct ophthalmoscopy method 
was used. Levels of diabetic retinopathy were noted. (Non 
proliferative or proliferative diabetic retinopathy with or without 
macular edema). 
Cardiovascular Disease  
 History of treatment for coronary artery disease was taken. A 
12 – lead baseline electrocardiogram was taken. Ischemic changes 
and infarction were looked for in ECG. Patients having these ECG 
changes were considered to  have coronary artery disease.  
Cerebrovascular Disease  
 History of cerebrovascular accidents, transient ischemic 
attacks, was taken. Patients were clinically examined for focal 
neurological deficit. Patients having either history of CVA, TIA or 
clinical evidence of focal neurological deficit were considered to 
have cerebrovascular disease.  
Peripheral Vascular Disease  
 History of lower extremity gangrene, amputation was taken. 
Clinically patients were examined for all peripheral pulses. A hand 
held Doppler ultrasound probe was used to measure to ankle 
brachial pressure index. The ankle brachial pressure index is the 
ratio of systolic pressure at the ankle to that in arm. Pressure 
recorded in the ankle was taken as numerator. Pressure recorded 
in the arm is taken as denominator. The resting ABPI is normally 
about 1.0. Patients with ABPI below 0.9 were considered to have 
peripheral vascular insufficiency.  
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RESULTS OF THE STUDY  
TABLE -1 
AGE DISTRIBUTION  
Diabetes with 
hypertension  
Diabetes without 
hypertension  
S.No Age in years  No. of 
Cases Percentage  
No. of 
Cases Percentage  
1 ≤ 40 1 2% 1 2% 
2 41 – 50  8 16% 7 14% 
3 51 – 60  19 38% 21 42% 
4 61 – 70  15 30% 17 34% 
5 >70 7 14% 4 8% 
  50  50  
  
The most common age interval in diabetes with hypertension 
group →  51- 60 years. 
The most common age interval in diabetes without 
hypertension group → 51- 60 years. 
Age  
Mean ± S.D 
Diabetes with hypertension  60.34 ± 9.7323 
Diabetes without hypertension  58.88 ± 8.5228 
P = 0. 213393 (Not significant) 
(Student t test) 
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TABLE – 2 
GENDER  
Diabetes  with 
hypertension 
Diabetes without 
hypertension Sex 
No of cases  % No of cases % 
Male  22 44 24 48 
Female  28 56 26 52 
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GENDER 
Male Female 
TABLE -3 
DURATION OF DIABETES MELLITUS  
Diabetes with 
hypertension 
Diabetes without 
hypertension  
Duration  of DM 
(years) No. 
cases % 
No. 
cases % 
1-5 5 10 4 8 
6-10 21 42 20 40 
11-15 15 30 21 42 
>15 9 18 5 10 
 
The most common duration of DM in diabetes with 
hypertension group 6 – 10 years. 
The most common duration of DM in diabetes without 
hypertension group 11-15 years.  
Duration of DM  
Mean ± SD 
Diabetes with hypertension  11.66 ± 5.6734 
Diabetes without hypertension  11.28 ± 4.7725 
P = 0.717811 (Not significant) 
(Student t test) 
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TABLE – 4 
DURATION OF HYPERTENSION IN DIABETES WITH 
HYPERTENSION GROUP  
Duration of hypertension 
(years) 
No. of Cases Percentage 
1-5 23 46 
6-10 22 44 
11-15 4 8 
>15 1 2 
Total  50 100 
 
Mean ± SD  = 6.46 ± 3.9186 
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TABLE – 5 
PERIPHERAL NEUROPATHY  
 
Peripheral Neuropathy 
Group 
Yes No 
Diabetes with 
hypertension  
32 18 
Diabetes without 
hypertension  
24 26 
Total  56 44 
 
P = 0.107039 (Not significant) 
(Chi – square test) 
Relative risk = 1.33 
The prevalence of peripheral neuropathy in diabetes with 
hypertension group = 64%. 
The prevalence of peripheral neuropathy in diabetes without 
hypertension group = 48%. 
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TABLE - 6 
DIABETIC NEPHROPATHY  
Diabetic Nephropathy 
Group 
Yes No 
Diabetes with 
hypertension 
12 38 
Diabetes without 
hypertension 
6 44 
Total 18 82 
 
P = 0.1183498 (Not significant)  
(Chi – square test) 
Relative risk = 2.00 
The prevalence of nephropathy in diabetes with 
hypertension group = 24%. 
The prevalence of nephropathy in diabetes without 
hypertension group = 12%. 
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 TABLE - 7 
DIABETIC RETINOPATHY 
Diabetic 
Retinopathy Group 
Yes No 
Diabetes with hypertension  18 32 
Diabetes without hypertension  8 42 
Total 26 74 
 
P = 0.0226193 
(Statistically significant) 
Relative risk = 2.25 
(Chi – square test) 
The prevalence of retinopathy in diabetes with 
hypertension group = 36%. 
The prevalence of retinopathy in diabetes without 
hypertension group = 16%. 
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TABLE - 8 
CORONARY ARTERY DISEASE  
Coronary 
Artery disease Group 
Yes No 
Diabetes with hypertension 17 33 
Diabetes without hypertension  5 45 
Total 22 78 
 
P = 0.003769 
(Statistically significant) 
(Chi square test)  
Relative risk  = 3.40 
The prevalence of coronary artery disease in diabetes 
with hypertension group = 34%. 
The prevalence of coronary artery disease in diabetes 
without hypertension group = 10%. 
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 TABLE – 9 
CEREBROVASCULAR DISEASE  
Cerebrovascular 
disease  Group 
Yes  No  
Diabetes with hypertension  4 46 
Diabetes without  hypertension 1 49 
Total 5 95 
 
P =  0.3621785 (Not significant) 
(Fisher exact two tailed test) 
Relative risk = 4 
The prevalence of cerebrovascular disease in diabetes 
with hypertension group = 8%. 
The prevalence of cerebrovascular disease in diabetes 
without hypertension group = 2%. 
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TABLE – 10 
PERIPHERAL VASCULAR DISEASE  
Peripheral 
Vascular Disease Group 
Yes No 
Diabetes with hypertension  3 47 
Diabetes without hypertension  1 49 
Total 4 96 
 
P = 0.6173071 (Not significant) 
(Fisher exact two tailed test) 
Relative risk = 3 
The prevalence of peripheral vascular disease in 
diabetes with hypertension group = 6% 
The prevalence of peripheral vascular disease in 
diabetes without hypertension group = 2% 
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Discus
sion 
DISCUSSION 
 The vascular complications of DM affect many organ systems 
and are responsible for majority of the mortality and morbidity 
associated with diabetes. Duration of DM is the Central Factor in 
the pathogenesis of these complications. Hypertension is a very 
common co-morbid condition in diabetes. In type 2 Diabetes, 
hypertension usually clusters with other components of 
cardiometabolic syndrome such as central obesity, Insulin 
resistance, dyslipidemia, microalbuminuria, hypercoagulation, 
increased PAI-1, hyperuricemia. Hypertension in diabetes has its 
specific characteristics like salt sensitivity and volume expansion, 
loss of nocturnal decline in BP, microalbuminuria, isolated systolic 
hypertension, orthostatic hypotension. 
 Hypertension worsens both microvascular and macrovascular 
complications, of diabetes. A large proportion of hypertensive 
diabetic patients show signs of target organ damage28, particularly 
affecting cardiovascular system. The deleterious effects of 
hypertension on left ventricular function are also accentuated by 
the presence of Diabetes. These include impaired LV relaxation72 
and increased left ventricular mass73, the later being an 
independent predictor of premature death from CAD. 
 The beneficial effects of strict BP control in type 2 diabetic 
patients has been demonstrated in UKPDS21. The most striking 
implication of UKPDS is the beneficial effects of strict BP control, 
than glycemic control in reducing microvascular disease as well as 
on all diabetes related end points. In this study, reduction in risk in 
the group assigned to tight BP control (144/82mmHg) compared 
with that assigned to less tight BP control (154/87 mmHg) were 
24% reduction in diabetes related end points,  32% in death related 
to diabetes, 44% in stroke and 37% in microvascular end points 
(Retinopathy and advanced nephropathy). 
 The hypertension optimal treatment (HOT) trial23 has 
demonstrated improved outcomes in patients assigned to lower 
blood pressure targets (51% risk reduction in cardiovascular 
outcomes in target group assigned to diastolic BP of 80mmHg 
compared with group assigned to a diastolic BP of 90mmHg). 
 JNC-VII60 has demonstrated the benefits of lowering BP in 
reducing the incidence of stroke (35-40%), MI (35-40%) and heart 
failure (50%). JNC-VII60 and ADA61 currently recommends a target 
BP of <130/80 mmHg in Diabetes and < 125/75mmHg in patients 
with > 1gm proteinuria per day and renal insufficiency. 
 Our study compared the prevalence of both the micro and 
macrovascular complications among type 2 DM between diabetic 
hypertensive and Diabetes without hypertension groups.  
 The prevalence of vascular complications in diabetic 
hypertensive group in our study are peripheral neuropathy 64%, 
nephropathy 24%, retinopathy 36%, coronary artery disease 34%, 
cerebrovascular disease 8% and peripheral vascular disease 6%. 
The prevalence of vascular complications in diabetes without 
hypertension group are peripheral neuropathy 48%, nephropathy 
12%; Retinopathy 16%, coronary artery disease 10%, 
cerebrovascular disease 2% and peripheral vascular disease 2%. 
 There is significant increase in the prevalence of coronary 
artery disease (P=0.003769) (RR=3.40) and retinopathy 
(P=0.0226193) (RR=2.25) in diabetic hypertensive group compared 
to diabetes without hypertension group. Though there is no 
statistical significance, there is increased prevalence of 
nephropathy (RR=2) in diabetic hypertensive group compared to 
diabetes without hypertension group. In our study, 
microalbuminuria was not done. The prevalence of nephropathy 
would have increased, if we had investigated for microalbuminuria. 
The prevalence of cerebrovascular disease is increased in diabetic 
hypertensive group compared to that of diabetes without 
hypertension group (RR = 4). The prevalence of peripheral vascular 
disease is increased in diabetic hypertensive group compared to 
that of diabetes without hypertension group (RR = 3). The 
prevalence of peripheral neuropathy in both groups showed no 
appreciable difference  
(RR =1.33).  
 A similar study conducted in Kilpauk Medical College74, 
Chennai in 1991 compared the prevalence of Macrovascular disease 
in type 2 Diabetes between Diabetic hypertensives and diabetic non 
hypertensives (1200 type 2 diabetic patients were studied). The 
results of that study are : the prevalence of coronary, cerebral and 
peripheral vascular events is diabetes with hypertension group 
were 34.61%, 5.77% and 5.77% respectively compared to 16.33%, 
4.59% and 1.53% respectively in diabetes without hypertension. 
This study concluded that diabetics with hypertension, compared to 
those without hypertension have a two fold increase in the 
prevalence of macrovascular events in general, as well as that of 
CAD and a 4 fold increase in the prevalence of PVD and there is no 
appreciable difference in the prevalence of cerebrovascular disease.  
 Our study results are comparable to the above study results.  
 From the results obtained in our study, diabetic hypertensive 
group has significant increased prevalence of vascular 
complications when compared to diabetes without hypertension 
group. The limitations of our study include smaller sample size, not 
investigated for micro albuminuria and lipid profile. Our study 
results signifies that hypertension is a definite risk factor in the 
development and progression of micro and macrovascular 
complication, in Type 2 DM. Apart from other factors such as 
smoking, dyslipidemia, obesity in the progression of vascular 
complications, hypertension plays a critical role in the progression 
of complications leading to increased mortality and morbidity in 
patients with type 2DM. JNC-VII has demonstrated the 
significance of strict BP control in patients with diabetes and 
lifestyle modification in diabetic prehypertensive stage in reducing 
diabetes related end points. Both JNC-VII60 and ADA61 
recommends a target BP of < 130/80mmHg in diabetic 
hypertensives and <125/75mmHg in patients with > 1gm 
proteinuria per day and significant renal disease. Apart from BP 
control, discontinuation of smoking, correction of dyslipidemia 
significantly reduces the development and progression of vascular 
complications of diabetes. 
  
 
 
 
 
Conclu
sion 
CONCLUSION 
 The conclusion obtained from the study results are : 
¾ The prevalence of coronary artery disease is significantly 
increased in diabetic patients with hypertension compared to 
diabetic patients without hypertension (P=0.003769). 
Diabetic patients with hypertension have more than three 
times risk of developing coronary artery disease, compared to 
diabetic patients without hypertension (RR=3.40). 
¾ The prevalence of diabetic retinopathy is significantly 
increased in diabetic patients with hypertension, compared to 
diabetic patients without hypertension (P=0.0226193). 
Diabetic patients with hypertension have more than two 
times increased risk of developing retinopathy than diabetic 
patients without hypertension (RR = 2.25).  
¾ Patients with diabetes and hypertension have 2 times 
increased risk of developing nephropathy than diabetic 
patients without hypertension (RR = 2). 
¾ Patients with diabetes and hypertension have 4 times 
increased risk of developing cerebrovascular disease than 
diabetic patients without hypertension (RR=4). 
¾ Patients with diabetes and hypertension have 3 times 
increased risk of developing peripheral vascular disease, than 
diabetic patients without hypertension (RR=3). 
¾ There is no appreciable difference in the prevalence of 
peripheral neuropathy between diabetic patients with 
hypertension and diabetic patients without hypertension.  
 From the study results obtained, it is concluded that patients 
with type 2 DM and hypertension have a higher prevalence of 
micro and macro vascular complications compared to those without 
hypertension. Hypertension is a definite risk factor in the 
development and progression of vascular complications. Therefore, 
meticulous control of hypertension in patients with diabetes is 
important in the prevention and in reducing the progression of 
vascular complications of diabetes.  
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CASE PROFORMA 
 
Name  : 
Age   : 
Sex   : 
Duration of DM :   Family H/o. DM : 
Duration of Hypertension :  Family H/o. Hypertension: 
 
Which came first DM/Hypertension ? 
H/o. Complications  
Neuropathy :   Coronary Artery Disease : 
Nephropathy :   Cerebrovascular Disease  : 
Retinopathy :   Peripheral Vascular Disease : 
 
Clinical Examination 
BP - 1. : 
- 2. : 
Pulse Rate  : 
Peripheral pulses  : 
Vascular Bruit  : 
Vascular Complications 
Neuropathy  
Monofilament : 
Biothesiometry : 
  Neuropathy : Mild / Moderate  / Severe  
Nephropathy  
Urine albumin – 1 : 
       - 2 : 
Urine Microscopy : 
Retinopathy 
 Fundus Examination : 
 Level of Retinopathy : 
Coronary artery disease 
 ECG 
Cerebrovascular disease  
 Focal neurological deficits : 
Peripheral vascular disease  
 Ankle brachial pressure index : 
 (Doppler Method) 
MASTER CHART 
Diabetes with Hypertension 
S.No Age Sex 
Duration 
of DM 
(Years) 
Duration of 
Hypertension  
(Years) 
Peripheral 
Neuropathy Nephropathy Retinopathy 
Cardio 
Vascular 
Disease 
Cerebro 
Vascular 
Disease 
Peripheral 
Vascular 
Disease 
1 61 M 1 2 + (Moderate) - + (Mild NPDR) - - - 
2 50 F 5 3 - - - - + (H/o. TIA) - 
3 58 F 5 5 + (Severe) - - - - - 
4 58 F 5 6 - - - + (IW Ischemia) - - 
5 60 F 6 4 + (Moderate) - + (Severe NPDR) + (AW Ischemia) - - 
6 63 F 8 1 + (Severe) - - - - - 
7 60 F 10 5 + (Moderate) + + (PDR) + (LW Ischemia) - + (ABPI Lt. = 0.59) 
8 75 M 7 7 - - - - - - 
9 44 F 7 7 + (Moderate) - - - - - 
10 55 F 10 2 - - - + (IW Ischemia) - - 
11 63 M 6 6 + (Severe) - - + (IW Ischemia) - - 
12 45 F 10 7 + (Moderate) - - - - - 
13 65 F 9 2 + (Severe) + + (Mild NPDR) - - - 
14 65 M 8 8 - - - - - - 
15 55 F 10 5 + (Moderate) - + (PDR) + (AL Ischemia) - - 
16 60 F 10 8 + (Moderate) - - + (AS Ischemia) - - 
17 39 M 8 8 - + + (Mild NPDR) + (Old ASMI) 
+ (H/o. 
CVA/Lt. 
Hemiparesis) 
- 
18 70 F 10 10 + (Moderate) - + (Moderate NPDR) - - - 
19 64 F 8 7 + (Severe) - + (PDR) - - - 
20 45 F 10 20 + (Severe) - + (Mild NPDR) + (IW Ischemia) - - 
21 56 M 11 2 + (Mild) - + (Mild NPDR) - - - 
22 61 M 13 6 - - - - - - 
23 50 F 12 7 + (Severe) - - - - - 
24 61 M 15 10 - - + (Mild NPDR) + (IW Ischemia) - - 
25 60 M 11 4 - + + (PDR) - - - 
26 70 F 13 13 - - - - - - 
27 77 M 15 10 + (Severe) - - - - - 
28 58 M 13 13 - + + (Mild NPDR) - - - 
29 52 M 11 8 + (Severe) - - - - - 
30 50 F 15 1 - + - - - - 
31 70 M 12 5 + (Moderate) - - + (IW Ischemia) - - 
32 57 F 12 6 - - - - - - 
33 53 F 12 3 + (Moderate) - - - - - 
34 60 F 10 3 + (Moderate) - - - - - 
35 69 M 10 10 - + + (Moderate NPDR) + (Old IWMI) - - 
36 60 F 11 3 + (Moderate) - - + (AL Ischemia) - - 
37 71 M 10 6 - - - + (LW Ischemia) - - 
38 45 F 8 13 + (Severe) - - - - - 
39 76 M 18 15 + (Severe) - - - - - 
40 56 M 12 5 + (Moderate) - - + (Old IWMI) - - 
41 56 M 18 4 + (Severe) + + (PDR) + (AL & IW Ischemia - - 
42 58 F 16 2 + (Moderate) + - - - - 
43 47 F 10 10 + (Severe) - - - - - 
44 79 M 20 10 + (Severe) - - - 
+ (H/o. 
CVA/Lt. 
Hemiparesis) 
- 
45 79 M 20 10 - - - - - - 
46 51 F 23 6 + (Severe) + + (Moderate NPDR) - - - 
47 70 M 24 5 - - - - - 
+ (H/o. 
Amputation 3rd 
Toe) 
48 72 M 32 4 - - + (PDR) - + (H/o. TIA) + (ABPI B/L = 0.5) 
49 68 F 20 3 + (Severe) + + (Mild NPDR) - - - 
50 70 F 3 3 + (Moderate) + - Recent ASMI - - 
           
 
 
NPDR - Non Proliferative Diabetic Retinopathy,    PDR - Proliferative Diabetic Retinopathy, IW - Inferior wall,   
IL - Inferolateral wall,   AL - Anterolateral,      ASMI - Anteroseptal Myocardial Infarction,  LW - Lateral wall,  
ABPI - Ankle Brachial Pressure Index, TIA - Transient Ischemic Attack, CVA - Cerebrovascular accident,  
IWMI - Inferior Wall Myocardial Infarction, AS - Antero Septal; + Presence of complications; - Absence of complications  
 
 MASTER CHART 
Diabetes without Hypertension 
S. 
No. Age Sex 
Duration 
of DM 
(Years) 
Peripheral 
Neuropathy Nephropathy Retinopathy 
Cardiovascular 
Disease  
Cerebrovascular 
Disease  
Peripheral 
Vascular 
Disease  
1 55 F 3 + (Moderate) - - - - - 
2 45 M 3 - - - - - - 
3 40 F 4 + (Moderate) - - - - - 
4 45 F 5 + (Mild) - - - - - 
5 65 F 6 - - - - - - 
6 50 F 6 - - - - - - 
7 64 M 6 - - - - - - 
8 74 M 7 + (Moderate) - - - - - 
9 79 M 6 - - - - - - 
10 68 M 9 - - - - - - 
11 48 M 10 - - - - - - 
12 63 F 10 + (Moderate) - - - - - 
13 54 M 10 + (Moderate) - - - - - 
14 62 M 10 - - - - - - 
15 60 M 7 - - - + (IW Ischemia) - - 
16 75 M 10 - + - - + (CVA / Lt. Hemiparesis) - 
17 66 F 12 + (Severe) - - + (IL Ischemia) - - 
18 57 F 12 + (Mild) - - - - - 
19 56 M 13 - - - - - - 
20 63 M 13 + (Moderate) - - + (AL Ischemia) - + (ABPI Lt.= 0.7) 
21 53 M 14 + (Moderate) + + (PDR) - - - 
22 66 M 14 - - - - - - 
23 50 F 12 - - - - - - 
24 67 M 13 + (Moderate) - + (Mild NPDR) - - - 
25 63 F 13 + (Severe) + - - - - 
26 54 M 13 - - - - - - 
27 60 M 12 + (Severe) + - - - - 
28 53 M 15 - - - - - - 
29 65 M 12 - - - - - - 
30 54 F 13 - - - - - - 
31 64 M 8 + (Mild) - - + (IW Ischemia) - - 
32 63 F 11 - - - - - - 
33 53 F 15 + (Moderate) - + (Mild NPDR) - - - 
34 63 F 10 - - - - - - 
35 53 F 10 + (Moderate) - - - - - 
36 54 F 10 - - - - - - 
37 58 F 10 - - - - - - 
38 55 F 12 - - - + (Old ASMI) - - 
39 67 F 12 + (Mild) - - - - - 
40 55 M 13 + (Severe) - + (Severe NPDR) - - - 
41 47 M 11 + (Moderate) + + (Moderate NPDR) - - - 
42 60 F 9 + (Moderate) - - - - - 
43 60 F 10 - - - - - - 
44 42 F 13 - - + (Mild NPDR) - - - 
45 57 F 18 + (Mild) - + (Moderate NPDR) - - - 
46 53 M 20 - - - - - - 
47 64 M 21 + (Moderate) - - - - - 
48 59 F 19 + (Severe) + - - - - 
49 70 F 9 - - - - - - 
50 73 F 30 + (Moderate) - + (Mild NPDR) - - - 
  
 
NPDR - Non Proliferative Diabetic Retinopathy,    PDR - Proliferative Diabetic Retinopathy, IW - Inferior wall,   
IL - Inferolateral wall,   AL - Anterolateral,      ASMI - Anteroseptal Myocardial Infarction,  ABPI - Ankle Brachial Pressure 
Index  
+ Presence of complications; - Absence of complications  
 
